NCT06104618View on ClinicalTrials.gov

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 21, 2023

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2026

Conditions
Metastatic Penile Squamous Cell CarcinomaStage III Penile Cancer AJCC v8Stage IV Penile Cancer AJCC v8Unresectable Penile Squamous Cell Carcinoma
Interventions
DRUG

Enfortumab Vedotin

Given IV

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (3)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

85054

RECRUITING

Mayo Clinic Hospital in Arizona, Phoenix

32224-9980

RECRUITING

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06104618 - Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis | Biotech Hunter | Biotech Hunter